I hope that is a roughly correct rendition of your argument.
Thanks for the great summary, Kave!
So this argument doesn’t bite for, say, shrimp welfare interventions, which could be arbitrarily more impactful than global health, or R&D developments.
Nitpick. SWP received 1.82 M 2023-$ (= 1.47*10^6*1.24) during the year ended on 31 March 2024, which is 1.72*10^-8 (= 1.82*10^6/(106*10^12)) of the gross world product (GWP) in 2023, and OP estimated R&D has a benefit-to-cost ratio of 45. So I estimate SWP can only be up to 1.29 M (= 1/(1.72*10^-8)/45) times as cost-effective as R&D due to this increasing SWP’s funding.
Here are my even-assuming-outside-view criticisms:
Even the Davidson model allows that the distribution for interventions that increase the rate/effectiveness of R&D (rather than just purchasing some at the same rate) could be much more effective. I think superresearchers (or even just a large increase in the number of top researchers) are such an intervention
To the extent we’re allowing cause-hopping to enable large multipliers (which we must to think that there are potentially much more impactful opportunities than superbabies), I care about superbabies because of the cause of x-risk reduction! Which I think has much higher cost-effectiveness than growth-based welfare interventions.
Fair points, although I do not see how they would be sufficiently strong to overcome the large baseline difference between SWP and general R&D. I do not think reducing the nearterm risk of human extinction is astronomically cost-effective, and I am sceptical of longterm effects.
Hi Stephen.
I find it interesting that you ranked LinkedIn last. Is this because many people working at the target organisations do not add their roles or organisations to their LinkedIn profiles?